MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

MDT

85.79

-1.48%↓

112.06

+1.49%↑

VEEV

175.19

+1.67%↑

HQY

81.65

-1.05%↓

CSBR

5.56

-0.89%↓

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

13.39 -4.36

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.12

Max

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.2M -12M
Werknemers	37
EBITDA	-2.1M -12M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+128.41% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-176M 1.2B
Vorige openingsprijs	17.75
Vorige sluitingsprijs	13.39

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

3.165 / 3.5827 Steun & Weerstand

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 mrt 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 mrt 2026, 22:36 UTC

Belangrijke Nieuwsgebeurtenissen

Australian Government Rules Out Boots on the Ground in the Middle East

30 mrt 2026, 22:13 UTC

Acquisities, Fusies, Overnames

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 mrt 2026, 21:00 UTC

Winsten

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 mrt 2026, 20:15 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 mrt 2026, 23:40 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 mrt 2026, 23:40 UTC

Marktinformatie

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 mrt 2026, 23:36 UTC

Marktinformatie

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 mrt 2026, 23:12 UTC

Marktinformatie

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 mrt 2026, 22:49 UTC

Marktinformatie

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 mrt 2026, 22:44 UTC

Marktinformatie

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 mrt 2026, 22:43 UTC

Marktinformatie

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 mrt 2026, 22:42 UTC

Marktinformatie

South32 Should Go for Growth, Says New Bull -- Market Talk

30 mrt 2026, 22:18 UTC

Marktinformatie

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 mrt 2026, 22:05 UTC

Marktinformatie

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 mrt 2026, 21:58 UTC

Acquisities, Fusies, Overnames

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 mrt 2026, 21:39 UTC

Acquisities, Fusies, Overnames

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 mrt 2026, 21:38 UTC

Acquisities, Fusies, Overnames

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 mrt 2026, 21:36 UTC

Acquisities, Fusies, Overnames

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 mrt 2026, 21:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 mrt 2026, 21:25 UTC

Marktinformatie

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 mrt 2026, 21:03 UTC

Acquisities, Fusies, Overnames

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 mrt 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

30 mrt 2026, 20:09 UTC

Winsten

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 mrt 2026, 20:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

128.41% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 32 USD 128.41%

Hoogste 42 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.165 / 3.5827Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.